Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)

被引：0
|
作者：
Normanno, N. [1 ]
Rachiglio, A. M. [1 ]
Abate, R. Esposito [1 ]
Orlandi, A. [2 ]
Maiello, E. [3 ]
Maglietta, G. [4 ,5 ]
Damato, A. [3 ]
Maiello, M. R. [1 ]
Carotenuto, M. [1 ]
Calegari, M. A. [2 ]
Antonuzzo, L. [6 ]
Bordonaro, R. [7 ]
Zampino, M. G. [8 ]
Tamberi, S.
Lonardi, S. [9 ]
Avallone, A. [10 ]
Latiano, T. P. [3 ]
Tamburini, E. [11 ]
Barone, C. A. [2 ]
Pinto, C.
机构：
[1] Ist Nazl Tumori IRCCS Fondazione G Pascale, Translat Res Dept, Naples, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Dept, Rome, Italy
[3] Med Oncol, IRCCS Fdn Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[4] Azienda Osped Univ Parma, Clin & Epidemiol Res Unit, Parma, Italy
[5] IRCCS, Azienda Osped Arcispedale Santa Maria Nuov, Reggio Emilia, Italy
[6] AOUC, Med Oncol Dept, Florence, Italy
[7] Dept Oncol, Azienda Osped ARNAS Garibaldi, Catania, Italy
[8] Osped Santa Maria Croci, Med Oncol, Ravenna, Italy
[9] IRCCS, Dept Oncol, IOV Ist Oncol Veneto, Padua, Italy
[10] IRCCS Fdn G Pascale, Ist Nazl Tumori, Abdominal Oncol Dept, Naples, Italy
[11] Azienda Osped Cardinale Giovanni Panico, Med Oncol, Tricase, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.122
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111P
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [31] Rechallenge with cetuximab 1 irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with
    Daniele, Rossini
    Daniele, Santini
    Chiara, Cremolini
    Lisa, Salvatore
    Sara, Lonardi
    Emanuela, Dell' Aquila
    Giuseppe, Aprile
    Fotios, Loupakis
    Bruno, Vincenzi
    Francesca, Battaglin
    Vanessa, Buoro
    Emiliano, Tamburini
    Deborah, Basile
    Domenico, Corsi
    Iacopo, Fioroni
    Gianluca, Masi
    Carlotta, Antoniotti
    Beatrice, Borelli
    Marzia, Del Re
    Giuseppe, Tonini
    Alfredo, Falcone
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris
    Steinbach-Buechert, Alma Katharina
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab every other week in the APEC study
    Cheng, A. -L.
    Cornelio, G. H.
    Shen, L.
    Prince, T. J.
    Yang, T. -S.
    Chung, I. -J.
    Dai, G.
    Lin, J. -K.
    Sharma, A.
    Yeh, K. -H.
    Ma, B.
    Zaatar, A.
    Guan, Z.
    Masood, N.
    Srimuninnimit, V.
    Yau, T. Cheung
    Beier, F.
    Chatterjee, S.
    Lim, R. S. C.
    ANNALS OF ONCOLOGY, 2015, 26 : 45 - 46
  • [34] IMPACT ON QUALITY OF LIFE OF CETUXIMAB PLUS FOLFIRI IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE CRYSTAL TRIAL
    Lang, I
    Aleknaviciene, B.
    Zolotukhin, S.
    Komissarenko, V
    Garcia-Alfonso, P.
    Jurga, L.
    Moiseyenko, V
    Filipczyk-Cisarz, E.
    Zubel, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 24
  • [35] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
    Kim, Ho Min
    Soda, Hitoshi
    Hazama, Shoichi
    Takahashi, Takao
    Nagata, Naoki
    Kotaka, Masahito
    Kono, Emiko
    Terada, Itsurou
    Fukunaga, Mutsumi
    Oba, Koji
    Hasegawa, Junichi
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [37] A phase II study of first-line chemotherapy initiating FOLFIRI plus cetuximab and switching to FOLFIRI plus bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial
    Shoji, H.
    Tsuda, T.
    Shimokawa, M.
    Akiyoshi, K.
    Tokunaga, S.
    Kunieda, K.
    Kotaka, M.
    Matsumoto, T.
    Nagata, Y.
    Mizukami, T.
    Mizuki, F.
    Danenberg, K.
    Sunakawa, Y.
    Boku, N.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S132 - S132
  • [38] Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Sheng
    Chung, Ilk Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Beler, Frank
    Chatterjee, Suipto
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [39] First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial
    Qin, S.
    Xu, J.
    Wang, L.
    Cheng, Y.
    Liu, T.
    Chen, J.
    Eggleton, S. P.
    Liu, J.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 141 - 141
  • [40] A phase Ib study of AUY922 and cetuximab in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Subramaniam, Somasundaram
    Goodman, Gary E.
    Boatman, Barry
    Smith, Andrew W.
    Iriarte, Desiree
    Gold, Philip Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345